Skip to main content
Withus Pharmaceutical. Co., LTD logo

Withus Pharmaceutical. Co., LTD — Investor Relations & Filings

Ticker · 330350 ISIN · KR7330350000 KO Manufacturing
Open in API
Filings indexed 119 across all filing types
Latest filing 2021-06-10 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 330350

About Withus Pharmaceutical. Co., LTD

https://withuspharm.com/

Withus Pharmaceutical. Co., LTD. is a pharmaceutical company engaged in the manufacturing and sale of prescription drugs. The company's product portfolio addresses a range of therapeutic areas, with a focus on circulatory agents, endocrine system treatments, and musculoskeletal drugs. Additionally, its offerings include antibiotics and medications for allergies.

Recent filings

Filing Released Lang Actions
권리락(무상증자)
Share Issue/Capital Change Classification · 1% confidence The document is a short announcement regarding a 'rights off' (권리락) event due to a bonus issue (무상증자) for Withus Pharmaceutical. It provides specific details about the stock code, reference price, and effective date. Since it announces a capital change event rather than being a full report or a share repurchase, it falls under the category of share issue/capital change announcements.
2021-06-10 Korean
[기재정정]사업보고서 (2020.12)
Annual Report Classification · 1% confidence The document is a 'Correction Report' (정정신고) for a previously filed 'Business Report' (사업보고서). In the context of Korean financial filings (DART system), a 'Business Report' is the equivalent of an Annual Report (10-K). This document provides specific corrections to sections of the original annual report, such as dividend information, articles of incorporation, and research and development activities. Since it is a formal amendment to an existing annual report, it is classified as an Annual Report (10-K) filing. FY 2020
2021-06-08 Korean
[기재정정]주요사항보고서(무상증자결정)
Share Issue/Capital Change Classification · 1% confidence The document is a 'Major Report' (주요사항보고서) from Withus Pharmaceutical Co., Ltd. regarding a 'Bonus Issue' (무상증자결정). It details the amendment of the listing date for new shares. Since this document relates to a change in capital structure (bonus issue/share issuance), it falls under the 'Share Issue/Capital Change' category.
2021-06-08 Korean
주요사항보고서(무상증자결정)
Share Issue/Capital Change Classification · 1% confidence The document is a 'Major Report' (주요사항보고서) from Withus Pharmaceutical Co., Ltd. regarding a decision for a bonus issue (무상증자결정). This involves a change in the company's capital structure through the issuance of new shares. According to the provided definitions, announcements regarding new share issues or capital changes fall under the 'Share Issue/Capital Change' (SHA) category.
2021-05-27 Korean
주권매매거래정지(무상증자)
Share Issue/Capital Change Classification · 1% confidence The document is a short regulatory notice regarding the suspension of stock trading for 'Withus Pharmaceutical' due to a bonus issue (free capital increase). It is a brief, formal announcement issued by the exchange or company regarding a specific market event, fitting the criteria for a general regulatory filing.
2021-05-27 Korean
분기보고서 (2021.03)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (분기보고서) for the first quarter of 2021 (제 18 기 1분기) for Withus Pharmaceutical Co., Ltd. It contains detailed financial information, business overviews, and management disclosures required by the Financial Supervisory Service and the Korea Exchange. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q1 2021
2021-05-14 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.